| INTRODUC TI ON
MET, the proto-oncogene, is a member of a distinct subfamily of heterodimeric receptor tyrosine kinases 1, 2 and encodes the high-affinity receptor for hepatocyte growth factor (HGF), which is the only known ligand for this receptor. 1 Dysregulation of MET signaling results in activation of downstream pathways, including the RAS/MAPK, PI3K/AkT, and Rac/ Rho pathways, which promote cell proliferation, survival and metastasis.
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Aberrant activation of the MET pathway may be a result of high-level MET gene amplification, protein overexpression or gene mutations, and is associated with resistance to chemotherapy and radiotherapy and poor clinical outcomes in cancer patients. [4] [5] [6] MET gene amplification typically occurs in approximately 3%-5% of newly diagnosed patients with NSCLC 7, 8 and is implicated in acquired resistance to EGFR TKI, reported in 5%-22% of cases with EGFR-inhibitor resistance, regardless of the presence of EGFR T790M mutation. 4, [9] [10] [11] Overexpression of MET and/or elevated levels of HGF have been described in multiple tumor types, including lung, breast, colon and gastric cancers. 3 MET protein overexpression has been reported in 20%-37% of tumor tissues, normally through transcriptional upregulation, 12, 13 whereas MET gene mutation in the splice site leading to exon 14 skipping [14] [15] [16] has been reported in 2%-4% of NSCLC adenocarcinoma and in 1%-2% of other NSCLC subsets. 17, 18 In addition, MET mutations have been identified in primary tumors as well as metastatic lesions of other cancers, including the head and neck, renal, liver and ovarian cancers. 19, 20 Capmatinib (INC280) is a highly specific, potent and selective MET inhibitor in biochemical (IC 50 , 0.13 nM) and cellular assays across a range of tumor types including NSCLC, which also causes regression of METdependent (amplified/autocrine) tumor models in animals at tolerable doses. Capmatinib has been demonstrated to be highly selective for MET kinase versus other kinases (10 000-fold selectivity in panel of 57 human kinases) in large panels of biochemical and binding assays. 21 Accordingly, a phase I, global, dose-escalation study of capmatinib was conducted in patients with MET-dependent solid tumors. The capsule formulation at 600 mg b.i.d. was initially selected as the RP2D. 22 A tablet formulation was subsequently developed to improve patient compliance, as this allowed for higher dosage strengths and therefore fewer tablets compared with capsules. The protocol was amended accordingly to add tablet formulation based on the results of a bioavailability study. Thus, the RP2D of capmatinib in tablet formulation was stated as 400 mg tablet b.i.d. in the global study.
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This phase I, multicenter, open-label, dose-escalation study (ClinicalTrials.gov Identifier: NCT01546428) was conducted in Japan to determine the MTD and/or the highest studied dose determined to be safe, safety, PK and preliminary antitumor activity of capmatinib in patients with advanced solid tumors (not selected based on their MET dysregulation status) who had progressed despite standard therapy or for whom no effective therapy exists.
| MATERIAL S AND ME THODS

| Study population
Adult Japanese patients with histologically or cytologically confirmed advanced solid tumors who were refractory to standard therapies or had tumors for which no effective treatment was available were The protocol and all the amendments were approved by the local institutional review board for each site that participated in the study and written consent was obtained from all patients before screening.
| Study design and treatment plan
This was an open-label, multicenter, dose-escalation, phase I study conducted across two centers in Japan. Patients received at least one dose of capmatinib daily in a 28-day cycle until disease progression, intolerable toxicity, withdrawal of consent or discontinuation for any other reason. Patients in subsequent cohorts received escalating doses of capmatinib (capsule or tablet formulation) until the MTD and/or highest studied dose determined to be safe was determined.
Dose escalation was guided by a 2-parameter BLRM employing the EWOC principle. 24, 25 The BLRM estimated the MTD by updating estimates of the probability of observing a DLT in the first cycle. A DLT was defined as a significant AE or abnormal laboratory parameter adjudged to be CTCAE, version 4.0, grade 3 or 4 in severity and considered unrelated to disease progression, intercurrent disease or concomitant medications, occurring 28 days or less following the first administration of the study treatment (cycle 1). For a given schedule, the MTD was defined as the highest drug dosage not expected to lead to DLT in more than 33% of patients in the first 28 days of capmatinib treatment under that schedule.
The primary objective was to determine the MTD and/or highest studied dose of single agent oral capmatinib determined to be safe. Secondary objectives included safety and tolerability, PK and preliminary antitumor activity of capmatinib. The exploratory objectives were to assess the effects on pharmacodynamic biomarkers for 
| Pharmacokinetics
Blood samples (3 mL) were collected at each time point on day 1 and day 15 of cycle 1. Capmatinib concentrations in plasma were measured using a validated liquid chromatography-mass spectrometry/mass spectrometry method with a lower limit of quantification of 1 ng/mL. The PK variables were classified into primary and secondary PK parameters. Primary PK parameters included AUC (AUC last , AUC inf , AUC tau ), C max and T max . The secondary PK parameters were terminal elimination rate constant, T 1/2 , apparent total body clearance of drug from the plasma, apparent volume of distribution during the terminal elimination phase, apparent volume of distribution during the terminal elimination phase at steady state and accumulation ratio. PK parameters were estimated using a noncompartmental method with Phoenix WinNonlin (version 6.4; Pharsight, Mountain View, CA, USA). Dose proportionality of capmatinib was assessed by formulation and regimen by using a power model on a logtransformed scale, that is, log (parameter) = log (α) + β × log (dose) + error.
The results based on the power model were also presented graphically by PK parameters using the estimates of α and β.
| Efficacy analysis
Computed tomography or magnetic resonance imaging-based tumor assessments were performed according to RECIST version 1.1.
| Biomarker analysis
Tumor tissues and blood samples were collected from all patients at different time points. Multiple biomarkers relevant to the mode of action of capmatinib such as MET mutation or amplification or overexpression, p-c-MET, p-ERK, p-AKT, p-S6 and HGF levels were analyzed. 
| Statistical analyses
| RE SULTS
| Patients
Between 10 patients (47.7%) received prior radiotherapy (Table 1 ).
All patients discontinued capmatinib treatment. The primary reason for discontinuation was disease progression, occurring in 38 patients (86.4%), followed by AE in four patients (9.1%) and loss to follow-up and subject/guardian decision in one patient (2.3%) each.
No on-treatment deaths (within 28 days after discontinuation of the study treatment) were reported.
| Safety
The median duration of treatment exposure was 7 weeks (range, the DLT events were suspected to be related to the study drug.
The suicidal ideation was reported as recovered because it was resolved after 1 day, and depression was reported as not recovered/ not resolved. In this study, the dose was escalated up to 400 mg 
Time from most recent relapse/ progression to first study drug (median, mo) No. of prior antineoplastic medication regimens, n (%) 4 (100) 4 (100) 4 (100) 3 (100) 3 (100) 12 ( All deaths including those that occurred more than 28 days after discontinuation of study treatment are counted.
b
On-treatment deaths occurring up to 28 d after discontinuation of study treatment are counted. AE, adverse event; SAE, serious adverse event.
TA B L E 3 AE occurring in more than 15% patients at all grades or at grade 3/4 regardless of study treatment relationship on-treatment deaths (within 28 days after discontinuation of study treatment) were reported. (n = 1), depression (n = 1), increased ALT and AST (n = 1), increased GGT (n = 1), hypophosphatemia (n = 1), decreased neutrophil count, decreased white blood cell count and hyponatremia (n = 1). There were no clinically meaningful changes or trends noted in vital signs and in ECG intervals. Treatment-emergent prolongation of QTcB of more than 450 ms was observed in three patients, more than 480 ms was observed in one patient and QTcB increase from baseline of more than 30 ms was reported in three patients.
| Pharmacokinetics
After single p.o. administration of capmatinib using capsule formulation on day 1, capmatinib was rapidly absorbed with median 
70.4
Results are based on the power model: log (parameter) = log (α) + β × log (dose) + error.
AUC, area under the curve; AUC last , AUC from time zero to the last quantifiable concentration point; AUC tau , AUC calculated to the end of the dosing interval; C max , maximum plasma drug concentration;
CV, coefficient of variation; PK, pharmacokinetic; T max , time to reach maximum plasma drug concentration.
| Efficacy
Overall, 37 patients (84.1%) had evaluable post-treatment tumor as- ( Figure 3 ). In these eight patients, the primary sites of cancer were the lung (n = 2), Ewing sarcoma (n = 1), malignant peripheral nerve sheath tumor (n = 1), esophagus (n = 1), oral cavity (n = 1), osteosarcoma (n = 1) and small intestine (n = 1).
| Biomarkers
Tumor samples were collected from all patients at the time of 
| D ISCUSS I ON
This phase I, dose-escalation study was conducted in Japanese patients with advanced solid tumors who had progressed despite standard therapy or for whom no effective therapy exists. The expansion was not initiated because sufficient data for further development were already available from other clinical studies of capmatinib. were reported during the study. Overall, capmatinib was well tolerated in Japanese patients, and the safety profile was similar to that observed in the global study. 
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